跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

GERPN3243

ECL Start Western Blotting Detection Reagent

Cytiva RPN3243, pkg of 200 mL

登录查看公司和协议定价

UNSPSC代码:
41105332
NACRES:
NA.32

保质期

Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.

包装

pkg of 200 mL

制造商/商品名称

Cytiva RPN3243

储存温度

room temp

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

Amersham ECL start is a chemiluminescent detection reagent in the Amersham ECL product family that is recommended for confirmatory analysis and detection of high to medium levels of endogenous proteins. Amersham ECL start has a long signal duration, which enables multiple exposures of the membrane, plus a convenient time window between experiment and analysis.

应用

ECL Start western blotting detection reagent has been used in western blotting.

特点和优势

  • Flexibility: Long signal duration provides assay design flexibility and robust detection of large experimental sets.
  • Low background: Produces low background, regardless of the method of detection.
  • Stability of the working solution: The working solution is stable for 5 days.
  • Long shelf life: A long shelf life of 18 months is convenient for those who run Western blots infrequently.

分析说明

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

法律信息

ECL is a trademark of Cytiva

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Grégoire Stik et al.
Nature genetics, 52(7), 655-661 (2020-06-10)
Three-dimensional organization of the genome is important for transcriptional regulation1-7. In mammals, CTCF and the cohesin complex create submegabase structures with elevated internal chromatin contact frequencies, called topologically associating domains (TADs)8-12. Although TADs can contribute to transcriptional regulation, ablation of
Starlee Lively et al.
Frontiers in cellular neuroscience, 12, 433-433 (2018-12-14)
Addressing potential sex differences in pre-clinical studies is crucial for developing therapeutic interventions. Although sex differences have been reported in epidemiological studies and from clinical experience, most pre-clinical studies of neuroinflammation use male rodents; however, sexual dimorphisms in microglia might
Starlee Lively et al.
Frontiers in cellular neuroscience, 12, 115-115 (2018-05-22)
The cytokine, transforming growth factor β1 (TGFβ1), is up-regulated after central nervous system (CNS) injuries or diseases involving microglial activation, and it has been proposed as a therapeutic agent for treating neuroinflammation. Microglia can produce and respond to TGFβ1. While

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门